Literature DB >> 17014395

Insulin aspart: a review.

David Owens1, Jiten Vora.   

Abstract

Insulin aspart, an analogue of human insulin, which is approved for use in people with diabetes, is more rapidly absorbed and achieves higher plasma concentrations than human soluble insulin following subcutaneous injection. Hence, it has a faster and more effective glucose-lowering action, with superior control of postprandial hyperglycaemia compared with human soluble insulin. Its shorter duration of action makes interprandial and nocturnal hypoglycaemia less of a problem than with human soluble insulin. Insulin aspart is approved for use in continuous subcutaneous infusion and offers a valuable treatment option during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17014395     DOI: 10.1517/17425255.2.5.793

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  5 in total

1.  Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.

Authors:  Daniel F Berenson; Allison R Weiss; Zhu-Li Wan; Michael A Weiss
Journal:  Ann N Y Acad Sci       Date:  2012-03-13       Impact factor: 5.691

2.  Insulin Aspart Combined with Exercise Therapy in Spleen Deficiency Type Gestational Diabetes Mellitus: The Effect on Disease Control and Pregnancy Outcomes.

Authors:  Yingkun Shi; Xueyun Meng
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-11       Impact factor: 2.650

Review 3.  Design of non-standard insulin analogs for the treatment of diabetes mellitus.

Authors:  V Pandyarajan; M A Weiss
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

4.  Safety of intravenous insulin aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience.

Authors:  Manoj Chawla; Harshad Malve; Harshvi Shah; Shwetal Shinde; Anil Bhoraskar
Journal:  J Diabetes Metab Disord       Date:  2015-04-03

Review 5.  The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies.

Authors:  Melanie Davies; Sudesna Chatterjee; Kamlesh Khunti
Journal:  Clin Pharmacol       Date:  2016-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.